Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Sinopharm CNBG COVID-19 vaccine

From Wikipedia, the free encyclopedia
Vaccine against COVID-19

For other uses, seeSinopharm COVID-19 vaccine.

Pharmaceutical compound
Sinopharm CNBG COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration
Intramuscular
Legal status
Legal status
Identifiers
CAS Number
Part ofa series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
virus iconCOVID-19 portal

Sinopharm NVSI COVID-19 vaccine, also known asmutI-tri-RBD orNVSI-06-08, is aCOVID-19 vaccine developed by National Vaccine & Serum Institute (NVSI, 中生研究院), a subsidiary of CNBG ofSinopharm.[2][3]

They claim to be the world's first "second generation broadly protective" recombinationprotein subunitvaccine, i.e. by combining three heterogeneousantigens into one single trimer RBD protein (突变集成三聚化RBD, mutI-tri-RBD).[4] It's based on the original, and theBeta (K417N/E484K/N501Y) andKappa (L452R/E484K) variants.[5]

References

[edit]
  1. ^"Patent Landscape Report COVID-19-related vaccines and therapeutics"(PDF).
  2. ^"Emergency use of Sinopharm's new CNBG protein vaccine approved in UAE".Gulf News. 27 December 2021. Retrieved27 December 2021.
  3. ^"China's new recombinant COVID-19 vaccine starts human tests". Xinhua. 25 April 2021. Retrieved5 May 2021.
  4. ^國藥集團:二代重組蛋白新冠疫苗保護效果良好
  5. ^Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, et al. (June 2022)."Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial".Nature Communications.13 (1): 3654.Bibcode:2022NatCo..13.3654K.doi:10.1038/s41467-022-31379-0.PMC 9237056.PMID 35760812.
logo
Development
Classes
Administration
Vaccines
Bacterial
Viral
Protozoan
Helminthiasis
Other
Inventors/
researchers
Controversy
Related
Pre-pandemic
2020
2021
2022
2023
Africa
Northern
Eastern
Southern
Central
Western
Asia
Central/North
East
Mainland China
South
India
By location
Southeast
Malaysia
Philippines
West
Europe
United Kingdom
By location
Eastern
Western Balkans
European Union
EFTA countries
Microstates
North
America
Atlantic
Canada
Caribbean
Countries
British Overseas Territories
Caribbean Netherlands
French West Indies
US insular areas
Central America
United States
responses
By location
Oceania
Australia
New Zealand
South
America
Others
Culture and
entertainment
Arts and
cultural heritage
Education
By country
Sports
By country
By sport
Society
and rights
Social impact
Labor
Human rights
Legal
Minority
Religion
Economic
By country
By industry
Supply and trade
Financial markets
Information
Misinformation
Politics
Political impact
Protests
International relations
Language
Others
Health issues
Medical topics
Testing and
epidemiology
Apps
Prevention
Vaccines
Topics
Authorized
DNA
Inactivated
mRNA
Subunit
Viral vector
Virus-like particles
In trials
Attenuated
DNA
Inactivated
RNA
Subunit
Viral vector
Virus-like particles
Deployment
by location
Africa
Asia
Europe
North America
Oceania
South America
Others
Treatment
Monoclonal antibodies
Small molecule antivirals
Specific
General
Institutions
Hospitals and
medical clinics
Mainland China
Others
Organizations
Health
institutes
Pandemic
institutes
Relief funds
People
Medical
professionals
Researchers
Officials
WHO
By location
Others
Data (templates)
Global
Africa
Americas
Asia
Europe
Oceania
Others
Portals:
Stub icon

This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Sinopharm_CNBG_COVID-19_vaccine&oldid=1290423750"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp